Checchi Capital Advisers LLC Has $863,000 Position in Pfizer Inc. (NYSE:PFE)

Checchi Capital Advisers LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,065 shares of the biopharmaceutical company’s stock after buying an additional 2,526 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Pfizer were worth $863,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Vanguard Group Inc. raised its position in shares of Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after buying an additional 2,285,276 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares in the last quarter. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter valued at $2,328,986,000. Massachusetts Financial Services Co. MA raised its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock valued at $1,548,889,000 after acquiring an additional 4,167,222 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $25.45 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market cap of $144.66 billion, a P/E ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The business’s fifty day moving average is $23.67 and its 200-day moving average is $24.84. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business posted $0.82 earnings per share. The company’s quarterly revenue was down 7.8% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

Several brokerages recently commented on PFE. Morgan Stanley boosted their price target on Pfizer from $31.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. BMO Capital Markets reduced their price objective on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. TD Cowen reduced their price target on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research report on Tuesday, April 22nd. Finally, HSBC reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.